Fonar Corporation (NASDAQ: FONR) |
|
Price: $16.2600
$0.25
1.562%
|
Day's High:
| $16.5
| Week Perf:
| 0.37 %
|
Day's Low: |
$ 15.97 |
30 Day Perf: |
6.76 % |
Volume (M): |
16 |
52 Wk High: |
$ 24.05 |
Volume (M$): |
$ 259 |
52 Wk Avg: |
$17.02 |
Open: |
$15.97 |
52 Wk Low: |
$14.05 |
|
|
Market Capitalization (Millions $) |
105 |
Shares
Outstanding (Millions) |
6 |
Employees |
520 |
Revenues (TTM) (Millions $) |
102 |
Net Income (TTM) (Millions $) |
13 |
Cash Flow (TTM) (Millions $) |
3 |
Capital Exp. (TTM) (Millions $) |
3 |
Fonar Corporation
FONAR Corporation is a research and development, production, and marketing company devoted to MRI technology. FONAR Corporation is a leading manufacturer of magnetic resonance imaging (MRI) ventilators, compatible patient monitoring equipment, and diagnostic solutions. The company has been in existence for over 40 years and was founded in 1978 by Dr. Raymond Damadian.
FONAR is based in Melville, New York and has its headquarters in the United States. It is publicly traded on the NASDAQ stock exchange and has a market capitalization of over $280 million. FONAR Corporation develops, assembles, and sells MRI scanners and related equipment under the brand name UPRIGHTe MRI. The Company also develops and markets their proprietary MRIs for stroke diagnosis and management (SPIN Scan) and the assessment of certain types of attention deficit disorder (Biomarkers).
FONAR Corporation's scanners offer the unique feature of being able to scan the patient in an upright, weight-bearing position. That means that the scanner can scan the body in the exact position it is in during normal activities. The upright scanning process offers unique advantages over traditional imaging methods, including early detection of spinal injuries and musculoskeletal conditions.
FONAR Corporation's UPRIGHTe MRI scanners are FDA approved and have received numerous patents over the years. These patents protect the innovative technology of the scanners and help differentiate the company from its competitors. The company's products are sold throughout North America, Europe, and Asia.
FONAR has won several awards and honors over the years. In 2014, the company was named to Forbes' list of America's 100 Best Small Companies. In 2018, FONAR received the Best Places to Work award from Long Island Business News. This award is a testament to the company's focus on employee satisfaction and its commitment to building a culture that fosters innovation, creativity, and collaboration.
In conclusion, FONAR Corporation is a leading manufacturer of MRI scanning equipment and related equipment. It is dedicated to developing and marketing innovative MRI scanning solutions that can detect a wide range of conditions and diseases. The company is committed to promoting an environment of innovation, creativity, and collaboration that is focused on improving the quality of life for patients, customers, and employees.
Company Address: 110 Marcus Drive Melville 11747 NY
Company Phone Number: 694-2929 Stock Exchange / Ticker: NASDAQ FONR
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Fonar Corporation
Fonar Corporation, a Medical Equipment & Supplies company, reported a break-even in the third quarter of 2024 with a moderate revenue improvement of 1.164% to $25.72 million. While this may seem like positive news, it is important to note that the company's business gains were below its peers in the same sector, with only a 6.53% rise compared to the previous year. Comparing it to the preceding reporting season, where the company reported no earnings per share and revenue growth of 1.308% to $25.39 million, the third quarter of 2024 showed a slight improvement. However, net earnings significantly declined by -44.64% to $2.483 million from $4.485 million in the corresponding period a year ago.
|
Fonar Corporation
Fonar Corporation, a leading Medical Equipment & Supplies company, has seen a significant improvement in its shares over the past few months. In the last three months, the company's shares have increased by 50.22%, indicating a strong upward momentum. Even in the trailing 30 days, Fonar Corporation shares improved by 6.01%, further supporting the positive trend. Currently, Fonar Corporation shares are only 2.6% away from reaching their 52-week high of $20.64. This suggests that the company's stock is gaining momentum and investors are optimistic about its future prospects.
|
Fonar Corporation
The first quarter of 2024 has been an exciting period for Fonar Corporation, a leading player in the Medical Equipment & Supplies sector. The company's financial performance has shown significant growth and improvement across multiple key metrics. With revenue surging, net earnings increasing, and profit margins expanding, Fonar Corporation appears to be on a promising path for future success. Let's delve into the implications of these results and their potential impact on the company. Revenue Growth Outperforms Industry Competitors: Fonar Corporation's first-quarter revenue for 2024 increased by an impressive 11.414% to $25.84 million. This growth can be attributed to the company's ability to capitalize on market opportunities and effectively meet customer demands. Notably, Fonar Corporation's revenue rise exceeded the average growth of 4.81% reported by its Medical Equipment & Supplies sector contemporaries. This achievement showcases the company's competitive edge and positions it favorably within the industry.
|
Fonar Corporation
In the recent fiscal period, Fonar Corporation, a prominent player in the Medical Equipment & Supplies sector, reported disappointing financial results. However, despite the challenges faced, there are reasons to be cautiously optimistic about the company's future performance. This article will provide an in-depth analysis of Fonar Corporation's financials and evaluate its potential for recovery. Financial Performance Fonar Corporation experienced a significant drop in its earnings per share (EPS) from $0.23 to -$1.16 compared to the same period last year. Meanwhile, its revenue showed moderate growth, with a 3.885% increase to $25.78 million. This growth, however, falls short of the 4.79% expected by the Medical Equipment & Supplies sector as a whole.
|
Fonar Corporation
Fonar Corporation, a medical equipment manufacturer, has posted a strong earnings report for the third quarter of 2023, outperforming results from the prior year. Income per share increased by 71.88% at $0.55 per share, with revenue growing modestly by 3.463% to $25.42 million. Comparing the figures to the preceding reporting season, the company realized a revenue of $24.26 million and a bottom line of $0.32 per share. The net earnings of Fonar Corporation in the financial third quarter of 2023 increased by 37.49% from net earnings of $3.262 million reported in the same period a year ago, reaching $4.485 million. Despite the operating margin falling to 16.39%, the company's net margin improved to 17.64% in the financial third quarter of 2023. However, operating earnings fell -26.09% to $4.167 million, resulting in a squeezing of the operating margin from 22.95% in the third quarter of 2022 to 16.39%.
|
Per Share |
Current |
Earnings (TTM) |
0.46 $ |
Revenues (TTM) |
15.86 $
|
Cash Flow (TTM) |
0.39 $ |
Cash |
0.02 $
|
Book Value |
24.69 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
0.46 $
|
Revenues (TTM) |
15.86 $ |
Cash Flow (TTM) |
0.39 $ |
Cash |
0.02 $
|
Book Value |
24.69 $ |
Dividend (TTM) |
0 $ |
|
|
|
Commercial Insurance Managed Care |
|
4.82 % |
of total Revenue |
Medicare Medicaid |
|
1.05 % |
of total Revenue |
Workers Compensation Personal Injury |
|
18.83 % |
of total Revenue |
Other Revenue Source |
|
5.3 % |
of total Revenue |
Medical Equipment |
|
8.64 % |
of total Revenue |
Management of Diagnostic Imaging Centers |
|
91.36 % |
of total Revenue |
|
|